(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 June 2009 (04.06.2009)

PCT

(10) International Publication Number
WO 2009/070298 A9

(51) International Patent Classification:
A01N 37/18 (2006.01) *A61K 38/00* (2006.01)

(21) International Application Number:
PCT/US2008/013146

(22) International Filing Date:
26 November 2008 (26.11.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/004,710	28 November 2007 (28.11.2007)	US
61/005,271	3 December 2007 (03.12.2007)	US
61/007,141	11 December 2007 (11.12.2007)	US
61/192,455	17 September 2008 (17.09.2008)	US

(71) Applicant *(for all designated States except BB, US)*: **TEVA PHARMACEUTICAL INDUSTRIES, LTD.** [IL/IL]; 5 Basel Street, P.O. Box 3190, 49131 Petach-Tikva (IL).

(71) Applicant *(for BB only)*: **TEVA PHARMACEUTICALS USA, INC.** [US/US]; 1090 Horsham Road, North Wales, Pennsylvania 19454 (US).

(72) Inventors: **STARK, Yafit**; Uziel 22, 54017 Giv'at Shmu'el 54017 (IL). **LADKANI, David**; Guatemala 29, Jerusalem 96705 (IL).

(74) Agent: **WHITE, John, P.**; Cooper & Dunham LLP, 30 Rockefeller Plaza, New York, NY 10112 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
1 July 2010

(15) Information about Correction:
see Notice of 1 July 2010

(54) Title: METHOD OF DELAYING THE ONSET OF CLINICALLY DEFINITE MULTIPLE SCLEROSIS

(57) Abstract: A method for delaying the onset of clinically definite multiple sclerosis in a patient at risk of developing clinically definite multiple sclerosis and retard long- term progression of multiple sclerosis and its symptoms, the method comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate to the patient, thereby delaying onset of clinically definite multiple sclerosis in the patient and retarding long-term progression of multiple sclerosis and its symptoms.

WO 2009/070298 A9